CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis

Stem Cells

Volumn 31, Issue 8, 2013, Pages 1467-1476

  Gassenmaier, Maximilian ^a   Chen, Dong ^a,b   Buchner, Alexander ^a,b   Henkel, Lynette ^c,d   Schiemann, Matthias ^c,d   Mack, Brigitte ^a   Schendel, Dolores J ^d   Zimmermann, Wolfgang ^a   Pohla, Heike ^a,d  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

AMD3100; Cancer stem cells; CXC chemokine receptor 4; Receptor tyrosine kinase inhibitors; Renal cell carcinoma

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; MESSENGER RNA; PAZOPANIB; PLERIXAFOR; SMALL INTERFERING RNA; SORAFENIB; SUNITINIB; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER SURVIVAL; CELL SUBPOPULATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; STEM CELL; TUMOR GROWTH;

AMD3100; CANCER STEM CELLS; CXC CHEMOKINE RECEPTOR 4; RECEPTOR TYROSINE KINASE INHIBITORS; RENAL CELL CARCINOMA;

ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; RECEPTORS, CXCR4; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84883354717     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1407     Document Type: Article

References (58)

1. Janzen NK, Kim HL, Figlin RA et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003;30:843-852.
2. Di Lorenzo G, Autorino R, Sternberg CN. Metastatic renal cell carcinoma: Recent advances in the targeted therapy era. Eur Urol 2009;56: 959-971.
3. Negrier S, Raymond E. Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs 2012;30:1791-1801.
4. Sosman JA, Puzanov I, Atkins MB. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res 2007;13:764s-769s.
5. Reya T, Morrison SJ, Clarke MF et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111.
6. Vermeulen L, de Sousa e Melo F, Richel DJ et al. The developing cancer stem-cell model: Clinical challenges and opportunities. Lancet Oncol 2012;13:e83-e89.
7. Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988.
8. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-5828.
9. Collins AT, Berry PA, Hyde C et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65: 10946-10951.
10. Bapat SA, Mali AM, Koppikar CB et al. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005;65:3025-3029.
11. Haraguchi N, Utsunomiya T, Inoue H et al. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006;24:506-513.
12. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445: 111-115.
13. Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030-1037.
14. Prince ME, Sivanandan R, Kaczorowski A et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007;104: 973-978.
15. Yang ZF, Ngai P, Ho DW et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 2008;47: 919-928.
16. Fang D, Nguyen TK, Leishear K et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005;65: 9328-9337.
17. Baccelli I, Trumpp A. The evolving concept of cancer and metastasis stem cells. J Cell Biol 2012;198:281-293.
18. Zhou BB, Zhang H, Damelin M et al. Tumour-initiating cells: Challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009;8:806-823.
19. Azzi S, Bruno S, Giron-Michel J et al. Differentiation therapy: Targeting human renal cancer stem cells with interleukin 15. J Natl Cancer Inst 2011;103:1884-1898.
20. Ginestier C, Liu S, Diebel ME et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010;120:485-497.
21. Dubrovska A, Kim S, Salamone RJ et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 2009;106:268-273.
22. Addla SK, Brown MD, Hart CA et al. Characterization of the Hoechst 33342 side population from normal and malignant human renal epithelial cells. Am J Physiol Renal Physiol 2008;295:F680-F687.
23. Zhong Y, Guan K, Guo S et al. Spheres derived from the human SKRC-42 renal cell carcinoma cell line are enriched in cancer stem cells. Cancer Lett 2010;299:150-160.
24. Bussolati B, Bruno S, Grange C et al. Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J 2008; 22:3696-3705.
25. Schendel DJ, Gansbacher B, Oberneder R et al. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 1993;151:4209-4220.
26. Djafarzadeh R, Noessner E, Engelmann H et al. GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing. Oncogene 2006;25:1496-1508.
27. Pastrana E, Silva-Vargas V, Doetsch F. Eyes wide open: A critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 2011;8:486-498.
28. Tang SW, Chang WH, Su YC et al. MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells. Cancer Lett 2009;273:35-43.
29. Duda DG, Kozin SV, Kirkpatrick ND et al. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: An emerging sensitizer for anticancer therapies? Clin Cancer Res 2011;17:2074-2080.
30. Creighton CJ, Li X, Landis M et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009;106:13820-13825.
31. Li T, Su Y, Mei Y et al. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest 2010;90:234-244.
32. Nakata S, Campos B, Bageritz J et al. LGR5 is a Marker of poor prognosis in glioblastoma and is required for survival of brain cancer stem-like cells. Brain Pathol 2013;23:60-72.
33. Su Y, Qiu Q, Zhang X et al. Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev 2010;19:327-337.
34. Zhang SS, Han ZP, Jing YY et al. CD133+CXCR4+ colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med 2012;10:85.
35. Costa WH, Rocha RM, Cunha IW et al. CD133 immunohistochemical expression predicts progression and cancer-related death in renal cell carcinoma. World J Urol 2012;30:553-558.
36. D'Alterio C, Cindolo L, Portella L et al. Differential role of CD133 and CXCR4 in renal cell carcinoma. Cell Cycle 2010;9:4492-4500.
37. Hermann PC, Huber SL, Herrler T et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1:313-323.
38. Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 1999;274:584-594.
39. Sanz-Rodriguez F, Guerrero-Esteo M, Botella LM et al. Endoglin regulates cytoskeletal organization through binding to ZRP-1, a member of the Lim family of proteins. J Biol Chem 2004;279:32858-32868.
40. Dubrovska A, Elliott J, Salamone RJ et al. CXCR4 expression in prostate cancer progenitor cells. Plos One 2012;7:e31226.
41. Dubrovska A, Hartung A, Bouchez LC et al. CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Br J Cancer 2012;107:43-52.
42. Ehtesham M, Mapara KY, Stevenson CB et al. CXCR4 mediates the proliferation of glioblastoma progenitor cells. Cancer Lett 2009;274: 305-312.
43. Jung MJ, Rho JK, Kim YM et al. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene 2013;32:209-221.
44. Miki J, Furusato B, Li H et al. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 2007;67: 3153-3161.
45. Ping YF, Yao XH, Jiang JY et al. The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. J Pathol 2011;224: 344-354.
46. Yang W, Wang C, Lin Y et al. OV6(+) tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma. J Hepatol 2012;57:613-620.
47. Kim M, Koh YJ, Kim KE et al. CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res 2010;70:10411-10421.
48. Brabletz T, Jung A, Spaderna S et al. Opinion: Migrating cancer stem cells - An integrated concept of malignant tumour progression. Nat Rev Cancer 2005;5:744-749.
49. Furusato B, Mohamed A, Uhlen M et al. CXCR4 and cancer. Pathol Int 2010;60:497-505.
50. Cho NH, Shim HS, Rha SY et al. Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. Eur Urol 2003;44:560-566.
51. Staller P, Sulitkova J, Lisztwan J et al. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003;425:307-311.
52. Negrier S, Raymond E. Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs 2012;30:1791-1801.
53. Huang D, Ding Y, Li Y et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 2010;70:1053-1062.
54. Xu L, Tong R, Cochran DM et al. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res 2005;65:5711-5719.
55. D'Alterio C, Portella L, Ottaiano A et al. High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer. Curr Cancer Drug Targets 2012;12:693-702.
56. Rhodes LV, Short SP, Neel NF et al. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res 2011;71: 603-613.
57. Singh S, Srivastava SK, Bhardwaj A et al. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: A novel target for therapy. Br J Cancer 2010;103:1671-1679.
58. Domanska UM, Kruizinga RC, Nagengast WB et al. A review on CXCR4/CXCL12 axis in oncology: No place to hide. Eur J Cancer 2013;49:219-230.